177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

NCT02088645 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Thyroid Cancer, Medullary
Neuroendocrine Tumor of the Lung Grade 1 and 2
Neuroendocrine Tumor of the Thymus Grade 1 and 2
Neuroendocrine Tumor GEP Grade 1-3

Interventions

DRUG: 177Lu-PP-F11N

Sponsor

University Hospital, Basel, Switzerland

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]